Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Phio Pharmaceuticals (NASDAQ: PHIO) has announced it will present new clinical data from its ongoing Phase 1b trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, TX from November 8-10, 2024. The presentation, titled 'INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma,' will be delivered by Dr. Mary Spellman on November 9, 2024. The company's proprietary INTASYL siRNA gene silencing technology is designed to enhance immune cells' effectiveness in killing tumor cells.

New clinical data from Phio's on-going Phase 1b trial to be presented

Marlborough, Massachusetts--(Newsfile Corp. - October 24, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL^® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new clinical data from the on-going Phase 1b clinical trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Houston, TX from November 8-10, 2024.

Presentation Details are as follows:

Title:	INTASYL PH-762: PD-1 Directed Intratumoral Immunotherapy for Cutaneous Carcinoma
Abstract Number:	696
Presenting Author:	Mary Spellman, M.D.
Date:	Saturday November 9, 2024
Location:	Exhibit Halls A and B, George R. Brown Convention Center

 

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on silencing specific genes using its proprietary INTASYL siRNA technology. INTASYL can target and silence virtually any gene with high specificity across a wide range of tissue types. INTASYL is primarily designed to enhance the ability of immune cells to kill tumor cells and can play a key role in improving adoptive cell therapy. Notably, INTASYL is the only self-delivering RNAi technology, in that does not require specialized formulations or drug delivery systems.

For additional information, visit the Company's website, www.phiopharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

Contact:
Phio Pharmaceuticals Corp.
Jennifer Phillips: jphillips@phiopharma.com
Corporate Affairs

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227533

FAQ

What clinical data will Phio Pharmaceuticals (PHIO) present at SITC 2024?

Phio Pharmaceuticals will present new clinical data from their ongoing Phase 1b trial of INTASYL PH-762, a PD-1 directed intratumoral immunotherapy for cutaneous carcinoma, at the SITC meeting on November 9, 2024.

When and where is Phio Pharmaceuticals (PHIO) presenting at SITC 2024?

Phio Pharmaceuticals is presenting on Saturday, November 9, 2024, at the Exhibit Halls A and B of the George R. Brown Convention Center in Houston, TX during the 39th Annual SITC Meeting.

What is the purpose of Phio Pharmaceuticals' (PHIO) INTASYL technology?

Phio Pharmaceuticals' INTASYL siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells.